Company Profile

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013.  HuniLife strives to develop efficacious therapeutics for the treatment of human diseases while aiming to bring long lasting value to our shareholders.  We are now developing new generation of novel drugs for unmet medical needs.

The ENO1-targeting therapeutic, HuL001, is a humanized monoclonal antibody for the treatment of immune diseases or cancers.  HuL001 is a novel First-in-Class drug to treat immune diseases or cancers owing to its unique mechanism of action (MOA).  ENO1-targeting antibody is derived from the collaboration efforts from Development Center for Biotechnology (DCB) and National Health Research Institute (NHRI) in Taiwan.  

In addition, HuniLife has continuous efforts to substantiate its R&D pipeline, which includes HuL002 (nanoparticle technology) and HuL003 (antibody drug conjugates, ADC) for the treatment of various cancers.  HuL002 was in-licensed from Shimadzu Corporation, a long-history renowned Japanese company specialized in clinical diagnosis and medical instruments.  HuL003 is a ENO1-based ADC for oncology application.

Vision

HuniLife is dedicated to address unmet medical needs and to deliver therapeutics valuable to patients through our innovative technologies and drug development.

Business Model

HuniLife is focusing on development of innovative and highly effective therapeutics.  Our business strategy is to in-license innovative technology or novel drug candidates, by taking them through various stages from preclinical development to clinical trial, and finally to establish partnership or out-license deal with pharmaceutical players.  We are actively pursuing collaboration or deal making opportunities with prestigious pharmaceutical companies to aggressively develop our drugs in pipeline.  Through such efforts, HuniLife is expected to gain substantial financial profit in a reasonable time frame.